Nuvation Bio Inc. (NUVB)
| Market Cap | 1.59B |
| Revenue (ttm) | 62.90M |
| Net Income (ttm) | -204.63M |
| Shares Out | 347.69M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,560,596 |
| Open | 4.590 |
| Previous Close | 4.560 |
| Day's Range | 4.460 - 4.620 |
| 52-Week Range | 1.570 - 9.750 |
| Beta | 1.61 |
| Analysts | Strong Buy |
| Price Target | 11.38 (+149.56%) |
| Earnings Date | May 4, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $11.38, which is an increase of 149.56% from the latest price.
News
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases NEW YORK, April 27, 2026 /PRNewswire/ -- N...
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients IBTROZI a...
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host...
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib Agreement provides Nuvation Bio ownership of global clinical development program,...
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and ot...
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NUVB--NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm.
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 ...
Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026
IBTROZI's launch has outpaced competitors with strong first-line growth, robust efficacy, and favorable safety, supported by evolving guidelines and efficient commercial execution. Pipeline assets, including safusidenib, show promising data and expansion into new indications.
Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference
Patient starts and revenue are growing, with first-line share increasing and strong product performance versus competitors. European expansion is on track, pipeline trials are advancing, and financials are robust with significant cash reserves and milestone payments expected.
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB). The investigation focuses on whether Nuva...
Nuvation Bio Earnings Call Transcript: Q4 2025
Full FDA approval and rapid U.S. launch of IBTROZI drove strong patient uptake and revenue growth, with global expansion underway and a robust cash position. Safusidenib advanced in pivotal trials for IDH1 mutant glioma, and the company expects first-line IBTROZI use to drive long-term growth.
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 Entered into exclusive ...
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hu...
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host ...
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol...
Nuvation Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ibtrozi has rapidly become the market leader in ROS1-positive NSCLC, showing best-in-class efficacy and tolerability, while safusidenib demonstrates superior results in glioma pivotal studies. Strong financials and recent partnerships support continued growth and new clinical milestones.
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter...
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of th...
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Fou...
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Nuvation Bio Transcript: Citi Annual Global Healthcare Conference 2025
Iptrozi’s launch for ROS1+ lung cancer has outpaced competitors, with strong efficacy, safety, and payer coverage, positioning it for major market share and revenue growth. Safusidenib’s promising data in glioma could unlock a large, durable market, while a robust cash position supports ongoing R&D and expansion.
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positiv...
Nuvation Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference
Major milestones included the AnHeart acquisition, Ibtrozi's FDA approval, and a robust commercial launch with strong physician feedback. Safusidenib showed best-in-class data in glioma, while the DDC platform pivots to new candidates. Focus remains on sales growth, trial enrollment, and business development.
Nuvation Bio Transcript: Jefferies London Healthcare Conference 2025
IBTROZI's launch exceeded expectations with strong uptake, robust efficacy, and favorable reimbursement, while pipeline asset safusidenib showed superior results in glioma. Management is confident in financial guidance, expects key partnerships and clinical milestones, and maintains a strong cash position.